Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study-Reference-Cited by-同舟云学术

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study

Published:2017-10-26 Issue:6 Volume:80 Page:1209-1217
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

van den Bent Martin,Gan Hui K.,Lassman Andrew B.,Kumthekar Priya,Merrell Ryan,Butowski Nicholas,Lwin Zarnie,Mikkelsen Tom,Nabors Louis B.,Papadopoulos Kyriakos P.,Penas-Prado Marta,Simes John,Wheeler Helen,Walbert Tobias,Scott Andrew M.,Gomez Erica,Lee Ho-Jin,Roberts-Rapp Lisa,Xiong Hao,Bain Earle,Ansell Peter J.,Holen Kyle D.,Maag David,Reardon David A.

Funder

AbbVie

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-017-3451-1/fulltext.html

Reference30 articles.

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiation Oncology G, National Cancer Institute of Canada Clinical Trials G (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466. doi: 10.1016/S1470-2045(09)70025-7

2. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 16(Suppl 4):iv1-63. doi: 10.1093/neuonc/nou223

3. Seystahl K, Wick W, Weller M (2016) Therapeutic options in recurrent glioblastoma–An update. Crit Rev Oncol Hematol 99:389–408. doi: 10.1016/j.critrevonc.2016.01.018